Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Cash from Financing Activities (2016 - 2025)

Prestige Consumer Healthcare (PBH) has 16 years of Cash from Financing Activities data on record, last reported at -$6.7 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 87.5% year-over-year to -$6.7 million; the TTM value through Dec 2025 reached -$129.5 million, up 45.84%, while the annual FY2025 figure was -$182.1 million, 24.45% up from the prior year.
  • Cash from Financing Activities reached -$6.7 million in Q4 2025 per PBH's latest filing, up from -$74.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $63.6 million in Q2 2021 and bottomed at -$83.7 million in Q1 2021.
  • Average Cash from Financing Activities over 5 years is -$40.9 million, with a median of -$53.7 million recorded in 2023.
  • The widest YoY moves for Cash from Financing Activities: up 167.11% in 2021, down 647.88% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at -$67.6 million in 2021, then soared by 85.18% to -$10.0 million in 2022, then tumbled by 547.07% to -$64.8 million in 2023, then rose by 16.93% to -$53.9 million in 2024, then skyrocketed by 87.5% to -$6.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$6.7 million in Q4 2025, -$74.9 million in Q3 2025, and -$36.3 million in Q2 2025.